PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC

Yongchang Zhang

Status and phase: Enrolling; Phase 2

Conditions: HER2 Insertion Mutation Positive Advanced NSCLC

Treatments: Drug: PD-1 Combined With Pyrotinib

Study type: Interventional

Funder types: Other

Identifiers

NCT04144569

POETHIS

Details and patient eligibility

About

The purpose of this study is to assess the safety and effectiveness of PD-1 Combined With Pyrotinib for First-line chemotherapy failed HER2 Insertion Mutation Positive Advanced Non-small Cell Lung Cancer

Enrollment: 30 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Advanced non-small cell lung cancer confirmed by histology or cytology
• HER2 insertion mutation-positive
• Failure with first-line standard chemotherapy
• with measurable lesions.

Exclusion criteria

• no measurable tumor lesions
• Patients received PD-1 or Pyrotinib before

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

30 participants in 1 patient group

PD-1 Combined With Pyrotinib

Experimental group

Description:

PD-1 combined With pyrotinib used fo first-line chemotherapy failedr HER2 Insertion mutation positive advanced NSCLC

Treatment:

Drug: PD-1 Combined With Pyrotinib